Medical Communications

Showing 15 posts of 6402 posts found.

60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study

July 22, 2024 Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials

60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …

GSK’s application for Blenrep for MM treatment accepted for EMA review

July 19, 2024 Medical Communications Blenrep, EMA, GSK, Oncology

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …

FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review

July 18, 2024 Medical Communications Atara Biotherapeutics, FDA, Virology, priority review

Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application

July 18, 2024 Medical Communications China, Everest Medicines, NMPA, Nephrology

Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …

NICE recommends digital tech for ADHD diagnosis in children and young people

July 16, 2024 Medical Communications ADHD, Diagnostics, NICE

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …

Biophytis gains IND approval from FDA for obesity study

July 11, 2024 Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

Roche gains CE Mark for AI glucose monitoring system for diabetes management

July 9, 2024 Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024 Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024 Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024 Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024 Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024 Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024 Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics

Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024 Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024 Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi

Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
The Gateway to Local Adoption Series

Latest content